6533b82dfe1ef96bd1291f21
RESEARCH PRODUCT
Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines
Ugur SahinÖZlem TüreciMathias Vormehrsubject
0301 basic medicineAnticancer immunityT-Lymphocytesmedicine.medical_treatmentTumor cellsCancer VaccinesGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineAntigens NeoplasmNeoplasmsAnimalsHumansMedicineMolecular Targeted TherapyPrecision Medicinebusiness.industryEffectorCancerGeneral MedicineImmunotherapymedicine.diseaseTreatment Outcome030104 developmental biology030220 oncology & carcinogenesisMutationCancer researchImmunotherapybusinessForecastingMajor histocompatibilitydescription
T cells are key effectors of anticancer immunity. They are capable of distinguishing tumor cells from normal ones by recognizing major histocompatibility complex–bound cancer-specific peptides. Accumulating evidence suggests that peptides associated with T cell–mediated tumor rejection arise predominantly from somatically mutated proteins and are unique to every patient's tumor. Knowledge of an individual's cancer mutanome (the entirety of cancer mutations) allows harnessing this enormous tumor cell–specific repertoire of highly immunogenic antigens for individualized cancer vaccines. This review outlines the preclinical and clinical state of individualized cancer vaccine development and the challenges ahead.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-01-27 | Annual Review of Medicine |